SPOP and prostate cancer: A recent study discovered a potential mechanism whereby the speckle-type POZ protein (SPOP) loss-of-function mutations could reduce ubiquitination-mediated PD-L1 degradation, leading to increased PD-L1 levels, accompanied by decreased TILs in both mouse tumors and human primary prostate cancer tissues [84].